In public safety, prohibiting certain animal experimentation, sale and testing; and imposing penalties.
SB 381 creates a new Chapter 58A in Title 35 of the Pennsylvania Consolidated Statutes to regulate and restrict the use of dogs and cats in research, testing, and related commercial activity, especially where Commonwealth funds are involved. The bill prohibits the use of state funds to directly support medically unnecessary research on dog or cat subjects in USDA pain/distress categories D or E, requires facilities receiving Commonwealth funds to comply with animal cruelty laws and the Whistleblower Law, and imposes adoption-related duties for animals that can be safely released after research. It also requires extensive disclosure and reporting by state agencies, institutions of higher education, and animal testing facilities about funding, species used, project purposes, adoptions, euthanasia, and efforts to reduce animal use.
The bill also restricts the sale of dogs and cats bred by persons with certain USDA violations, requires recordkeeping for breeders and kennels supplying research animals, and gives the Department of Agriculture authority to revoke licenses for certain federal animal-cruelty convictions. In addition, it bars product testing facilities from using traditional animal test methods when an approved alternative exists or a waiver has been granted, and it prohibits the sale in Pennsylvania of cosmetics developed or manufactured using animal tests conducted on or after January 1, 2027, subject to specified exceptions. Enforcement is centered on the Attorney General, the Department of Agriculture, and the Treasury Department, and the act takes effect in 180 days.
SB 381 would add a new regulatory framework governing animal experimentation, animal sourcing, adoption, reporting, and certain product and cosmetic testing practices in Pennsylvania. It would affect Commonwealth agencies, state-related and state-owned higher education institutions, private research facilities, kennels, dealers, and cosmetic manufacturers or product testing facilities doing business in the Commonwealth. The bill also amends the practical operation of the Dog Law and interacts with state cruelty, licensing, reporting, and whistleblower provisions, while creating new disclosure obligations and potential funding suspensions for noncompliance.
The voting history indicates broad bipartisan support for the bill, with unanimous or near-unanimous committee and floor votes and final passage by a 50-0 Senate vote. The absence of recorded committee transcripts limits direct insight into debate, but the strong vote margins suggest the measure was generally viewed favorably across caucuses. The bill’s repeated amendment and re-reporting history also suggests it was refined during the legislative process rather than being highly divisive.
The main areas of potential contention are the bill’s restrictions on animal research and testing, especially the limits on Commonwealth funding, the mandatory adoption and reporting requirements, and the prohibition on selling cosmetics developed with post-2027 animal testing. Research institutions, testing facilities, and industry stakeholders may view the reporting burdens, funding restrictions, and product-testing limits as operationally significant, while animal welfare advocates are likely to support them. Another possible point of debate is the scope of exceptions for biomedical research, federally required testing, and foreign regulatory testing, which appear designed to balance animal welfare goals with scientific and commercial compliance needs.